Should the First Amendment protect information, such as financial advice and marketing strategies that a drug maker provides to doctors? Or could this constitute a bribe under a federal kickback law?. These questions have taken on a contentious role in a whistleblower lawsuit filed by a pair of ophthalmologists, who claim Allergan induced physicians to prescribe its Restasis treatment for chronic dry eye and other medicines by offering different sorts of information to improve their practices. But the way that Allergan interprets and defends these actions has riled the federal government.